Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 10, 2011, Pages 1874-1875

  Beyer, Christian ^a   Axmann, Roland ^b   Sahinbegovic, Enijad ^a   Distler, Jörg H ^a   Manger, Bernhard ^a   Schett, Georg ^a   Zwerina, Jochen ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TOCILIZUMAB;

AGED; ANOREXIA; ARTERIAL WALL THICKENING; BLOOD VESSEL BIOPSY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIPLOPIA; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEMORAL ARTERY; FEVER; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; HEADACHE; HUMAN; IRIDOCYCLITIS; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NIGHT SWEAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL VESSEL VASCULITIS; TEMPORAL ARTERY; VISUAL DISORDER; WEIGHT REDUCTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, INTERLEUKIN-6; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052495918     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.149351     Document Type: Letter

References (9)

1. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum 2003;49:703-708 (Pubitemid 37296477)
2. Hernández-Rodríguez J., García-Martínez A., Casademont J., et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002;47:29-35. (Pubitemid 34137341)
3. Dasgupta B., Borg F.A., Hassan N., et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010;49:1594-1597
4. Hachulla E., Boivin V., Pasturel-Michon U., et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001;19:171-176 (Pubitemid 32372453)
5. Weyand C.M., Hicok K.C., Hunder G.G., et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-491
6. Roche N.E., Fulbright J.W., Wagner A.D., et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-1294 (Pubitemid 23303119)
7. Bossert M., Prati C., Balblanc J.C., et al. Aortic involvement in giant cell arteritis: Current data. Joint Bone Spine 2010;(In Press).
8. Hunder G.G., Bloch D.A., Michel B.A., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-1128 (Pubitemid 20273297)
9. Hernández-Rodríguez J., Segarra M., Vilardell C., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-2434 (Pubitemid 36605224)